Max Robotics — Global Service Robot Directory + US Certification

About

Hans Garmo is a leading epidemiologist whose research focuses on the long-term outcomes and patient-reported experiences following treatment for urological cancers, particularly prostate and bladder cancer. His major contributions lie in leveraging large, nationwide, population-based registries to provide real-world evidence on treatment side effects, moving beyond clinical trials to capture the true patient experience. Notably, his landmark 2024 study on patient-reported side effects one year after prostate cancer treatment, which has already garnered 33 citations, provides critical, contemporary data on the prevalence of urinary, bowel, and erectile dysfunction following radical prostatectomy or radiotherapy. This work is essential for shared decision-making between clinicians and patients. Garmo has also advanced the field by comparing short-term outcomes of robot-assisted versus open cystectomy for bladder cancer, using a nationwide cohort to inform surgical practice. Through his rigorous, register-based methodology, Garmo’s research directly impacts clinical guidelines and patient quality of life, making him a pivotal figure in evidence-based urological oncology.